FACT · Insider Trading
FACT II Acquisition Corp. Class A Ordinary Shares
Every open-market purchase and sale reported by FACT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2010-04-21 | Maninder Hora | VP, Prod Ops. & Quality | U | −7,516 | −$202.93K |
| 2010-04-21 | Kurt Von Emster | Director | U | −8,333 | −$224.99K |
| 2010-04-21 | Gary A Lyons | Director | U | −8,333 | −$224.99K |
| 2010-04-21 | Ted Llana | SVP Comm'l & Corp. Dev | U | −2,989 | −$80.70K |
| 2010-04-21 | Herb Cross | VP of Finance/Prin Acctg Off | U | −5,281 | −$142.59K |
| 2010-04-21 | Bradford S Goodwin | Director | U | −10,000 | −$270.00K |
| 2010-04-21 | BAUPOST GROUP LLC/MA | 10%+ Owner | U | −4,500,000 | −$121.50M |
| 2010-04-21 | Andrew Guggenhime | SVP & CFO | U | −12,383 | −$334.34K |
| 2010-04-21 | Francis Willard Sarena | VP Gen Counsel & Secy | U | −9,875 | −$266.62K |
| 2010-04-21 | Faheem Hasnain | President & CEO | U | −18,463 | −$498.50K |
| 2010-04-21 | Mark Rolfe | Sr. Vice Pres. and CSO | U | −1,113 | −$30.05K |
| 2010-04-21 | David Ross Parkinson | Director | U | −8,333 | −$224.99K |
| 2010-04-21 | Amber Acquisition Inc. | 10%+ Owner | MIXED | +137,264,178 | +$3.71B |
| 2010-04-12 | SAK CORP | 10%+ Owner | Sell | −1,500,000 | −$40.44M |
| 2010-04-05 | Andrew Guggenhime | SVP & CFO | F | −1,516 | −$40.90K |
| 2010-03-17 | SAK CORP | 10%+ Owner | Sell | −4,520,625 | −$122.06M |
| 2010-02-09 | BIOTECHNOLOGY VALUE FUND L P | — | Buy | +235,200 | +$3.64M |
| 2010-02-04 | BVF INVESTMENTS LLC | — | Buy | +940,494 | +$14.74M |
| 2010-01-29 | BVF INVESTMENTS LLC | — | Buy | +1,629,600 | +$25.57M |
| 2010-01-25 | Herb Cross | Corp Controller/Prin Acctg Off | F | −1,319 | −$20.68K |
| 2010-01-22 | Ted Llana | SVP Commercial & Corporate Dev | F | −2,344 | −$40.76K |
| 2009-12-22 | Herb Cross | Corp Controller/Prin Acctg Off | F | −202 | −$3.64K |
| 2009-10-05 | Faheem Hasnain | President & CEO | F | −8,937 | −$155.24K |
| 2009-09-22 | Ted Llana | SVP, Comm'l & Corp. Dev. | A | +15,000 | — |
| 2009-09-15 | Francis Willard Sarena | VP, Gen Counsel & Secy | F | −1,182 | −$19.31K |
| 2009-09-15 | Herb Cross | Corp Controller/Prin Acctg Off | F | −1,379 | −$22.53K |
| 2009-09-09 | Hoyoung Huh | Director | A | +8,333 | — |
| 2009-09-08 | Seth A Klarman | 10%+ Owner | Sell | −2,602,596 | −$40.15M |
| 2009-08-20 | Mark Rolfe | Sr. Vice Pres. and CSO | A | +21,333 | — |
| 2009-08-10 | Andrew Guggenhime | SVP & CFO | A | +15,251 | — |
| 2009-08-10 | Ted Llana | SVP, Comm'l & Corp. Dev. | A | +8,896 | — |
| 2009-08-10 | Faheem Hasnain | President & CEO | A | +27,667 | — |
| 2009-08-10 | Maninder Hora | VP, Prod. Ops. & Quality | A | +5,325 | — |
| 2009-08-10 | Francis Willard Sarena | VP, Gen Counsel & Secy | A | +6,923 | — |
| 2009-08-10 | Herb Cross | Corp Controller/Prin Acctg Off | A | +4,500 | — |
| 2009-07-28 | Maninder Hora | VP Product Operations & Quali | F | −492 | −$4.07K |
| 2009-05-28 | Bradford S Goodwin | Director | A | +3,334 | — |
| 2009-05-28 | David Ross Parkinson | Director | A | +2,500 | — |
| 2009-05-28 | Kurt Von Emster | Director | A | +1,667 | — |
| 2009-05-28 | Gary A Lyons | Director | A | +2,500 | — |
| 2009-04-06 | Herb Cross | Corp Controller/Prin Acctg Off | A | +6,866 deriv. | — |
| 2009-04-06 | Mark Anthony McCamish | Sr. VP & Chief Medical Officer | A | +19,045 deriv. | — |
| 2009-04-06 | Andrew Guggenhime | SVP & CFO | D | −1,478 | −$14.47K |
| 2009-04-06 | Francis Willard Sarena | VP General Counsel & Secretar | A | +6,422 deriv. | — |
| 2009-04-06 | Maninder Hora | VP Product Operations & Quali | A | +16,856 deriv. | — |
| 2009-02-24 | Kurt Von Emster | Director | A | +8,333 | — |
| 2009-02-23 | Mark Anthony McCamish | Sr. VP & Chief Medical Officer | F | −1,780 | −$11.68K |
| 2009-02-02 | Francis Willard Sarena | VP, Gen Counsel & Secy | F | −474 | −$2.88K |
| 2009-01-27 | Bradford S Goodwin | Director | A | +10,000 | — |
| 2009-01-27 | Mark Anthony McCamish | Sr. VP & Chief Medical Officer | A | +12,405 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FACT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.